CN105995425A - 一种药食同源的具有改善睡眠功能的组合物及其应用 - Google Patents
一种药食同源的具有改善睡眠功能的组合物及其应用 Download PDFInfo
- Publication number
- CN105995425A CN105995425A CN201610342991.0A CN201610342991A CN105995425A CN 105995425 A CN105995425 A CN 105995425A CN 201610342991 A CN201610342991 A CN 201610342991A CN 105995425 A CN105995425 A CN 105995425A
- Authority
- CN
- China
- Prior art keywords
- parts
- function
- portions
- sleep
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 22
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 22
- 229920001353 Dextrin Polymers 0.000 claims abstract description 13
- 239000004375 Dextrin Substances 0.000 claims abstract description 13
- 235000019425 dextrin Nutrition 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 210000000582 semen Anatomy 0.000 claims description 33
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 17
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 claims description 13
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 claims description 13
- 235000005903 Dioscorea Nutrition 0.000 claims description 9
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 9
- 235000004879 dioscorea Nutrition 0.000 claims description 9
- 235000008216 herbs Nutrition 0.000 claims description 7
- 230000010354 integration Effects 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 230000005059 dormancy Effects 0.000 claims 2
- 244000281702 Dioscorea villosa Species 0.000 claims 1
- 229920000157 polyfructose Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 14
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 235000007215 black sesame Nutrition 0.000 abstract 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract 1
- 229940107187 fructooligosaccharide Drugs 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000006870 function Effects 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 13
- 238000003304 gavage Methods 0.000 description 13
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 11
- 229960002275 pentobarbital sodium Drugs 0.000 description 11
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 9
- 241000234273 Dioscorea Species 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 206010022437 insomnia Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229960000796 barbital sodium Drugs 0.000 description 4
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 4
- 206010003084 Areflexia Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 230000004620 sleep latency Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000008098 Oxalis acetosella Nutrition 0.000 description 2
- 241001119526 Paullinia Species 0.000 description 2
- 235000010240 Paullinia pinnata Nutrition 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RANQPHKSRUUPKK-UHFFFAOYSA-N 3-O-[alpha-L-arabinofuranosyl-(1->2)-O-{beta-D-glucopyranosyl-(1->3)}-(alpha-L-arabinopyranosyl)]jujubogenin Natural products CC(C)=CC1CC(C)(O)C2C3CCC4C5(C)CCC(OC6OCC(O)C(OC7OC(CO)C(O)C(O)C7O)C6OC6OC(CO)C(O)C6O)C(C)(C)C5CCC4(C)C33COC2(C3)O1 RANQPHKSRUUPKK-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 241001149422 Ganoderma applanatum Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229930192286 jujuboside Natural products 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开了一种药食同源的具有改善睡眠功能的组合物,所述具有改善睡眠功能的组合物由以下重量份的组分组成:4‑8份酸枣仁,8‑12份桂圆,4‑8份茯苓,5‑9份百合,2‑6份开边红莲,20‑28份黑芝麻,16‑22份山药,18‑22份燕麦,2‑4份抗性糊精,1‑2份低聚果糖。本发明的具有改善睡眠功能的组合物全部由药食同源的中药组成,通过各组分的协同增效,发挥复方中药的整体调节优势,无毒副作用,具有较好的改善睡眠作用,疗效确切。
Description
技术领域
本发明涉及保健品技术领域,尤其是涉及一种具有改善睡眠功能的药食同源的组合物。
背景技术
失眠是指持续的睡眠质或量令人不满意的状态,严重者甚至影响白天社会功能,临床表现为入睡困难、睡眠不深、易惊醒、早醒、多梦、醒后疲乏,或缺乏清醒感,警觉性、精力、认知功能、行为和情绪的变化等。失眠比较常见,严重影响了人们的正常工作生活。国际睡眠基金会在美国的一项大规模民意调查发现,56%的美国人在一周内有几个晚上至少有一次失眠的症状,其中包括入睡困难、或夜间觉醒、或早醒、或醒后感觉不清等症状。我国严重失眠症的发病率为9.38%,严重影响了人们的正常生活和工作。
失眠的治疗,临床常用镇静催眠类西药虽然疗效较好,但都出现不同程度的头晕、乏力、困倦、注意力不集中,甚至暂时性健忘和宿醉现象等不良反应,尤其会产生明显的依赖性。中药治疗失眠保健效果稳定、不良反应少、经济实惠,其多靶点、多环节、多途径的药理作用是使中药具有独到的优势。
发明内容
本发明的目的在于提供一种具有改善睡眠功能的组合物,其以药食同源的中药研制而成,疗效确切,无毒副作用。
为了实现上述目的,本发明采用以下技术方案:
本发明的一种具有改善睡眠功能的组合物,所述具有改善睡眠功能的组合物由以下重量份的组分组成:4-8份酸枣仁,8-12份桂圆,4-8份茯苓,5-9份百合,2-6份开边红莲,20-28份黑芝麻,16-22份山药,18-22份燕麦,2-4份抗性糊精,1-2份低聚果糖。本发明的具有改善睡眠功能的组合物以药食同源的天然中药研制而成,其中,酸枣仁为鼠李科植物酸枣的干燥成熟种子,味甘、酸,性平。归心肝胆经。功效养心益肝,安神,敛汗。明代李时珍《本草纲目》中记载,枣仁“熟用疗胆虚不得眠,烦渴虚汗之症;生用疗胆热好眠,皆足厥阴少阳药也。,,现代药理研究表明,酸枣仁对小鼠、大鼠、豚鼠、猫、兔、及犬均有镇静催眠作用。酸枣仁中酸枣仁皂苷具有较好的改善睡眠的作用;桂圆(龙眼肉)为无患子科植物龙眼的假 种皮,甘温,归心、脾经,功效补益心脾,养血安神。李时珍说:“龙眼大补”“食品以荔枝为贵,而资益则龙眼为良。”《日用本草》:“益智宁心。”桂圆(龙眼干)含有大量的铁、钾等元素,能促进血红蛋白的再生以治疗因贫血造成的心悸、心慌、失眠、健忘。桂圆(龙眼干)中含尼克酸高达2.5毫克(每100克),可用于治疗尼克酸缺乏造成的皮炎、腹泻、痴呆,甚至精神失常等;茯苓是拟层孔菌科真菌茯苓的干燥菌核,甘、淡,平。归心、肺、睥、肾经。利水渗湿,健脾补中,宁心安神。用于心悸怔忡,失眠健忘。本品既能益心脾而宁心,又能交心肾而安神。茯神煎剂腹腔注射,能明显降低小鼠的自发活动,并能对抗咖啡因所致小鼠过度兴奋作用。茯苓煎剂小鼠腹腔注射对戊巴比妥钠的麻醉作用有明显的协同;百合,甘、微苦、微寒,归心、肺经。养阴润肺,清心安神。百合具有镇静安神作用,如小鼠停食8小时后,分别百合20g/kg,用酸枣仁作阳性对照,空白用生理盐水,给药30分钟ip戊巴比妥钠40mg/kg,以翻正反射消失到恢复的时间作为睡眠时指标。同时观察对戊巴比妥钠阈下剂量睡眠率的影响。均具有显着地增加戊巴比妥钠睡眠时间及阈下剂量的睡眠率,提示有明显的镇静作用;开边红莲,味甘、涩,性平。归脾、肾、心经。补脾止泻,止带,益肾涩精,养心安神。用于脾虚泄泻,带下,遗精,心肾不交、虚烦失眠。现代研究表明莲子具有具有收敛、镇静作用;黑芝麻,甘平,归肝肾大肠经。可以补中益气,养五脏。具有补益精血、润燥滑肠之功效。现代研究表明其具有抗衰老作用、抑制肾上腺皮质功能、降血糖作用等;山药,药性甘平,归脾肺肾经。具有益气养阴,补脾肺肾,固精止带的功效。现代研究表明其可补肾强身,增强抵抗力,可以起到较好的保健养生功效。本发明通过各组分的协同增效,具有较好的睡眠改善作用。
作为优选,所述具有改善睡眠功能的组合物由以下重量份的组分组成:5-7份酸枣仁,9-11份桂圆,5-7份茯苓,6-8份百合,3-5份开边红莲,22-26份黑芝麻,18-21份山药,19-21份燕麦,2-4份抗性糊精,1-2份低聚果糖。
作为优选,所述具有改善睡眠功能的组合物由以下重量份的组分组成:6份酸枣仁,10份桂圆,6份茯苓,7份百合,4份开边红莲,24份黑芝麻,19份山药,20份燕麦,3份抗性糊精,1份低聚果糖。
一种具有改善睡眠功能的组合物在食品及保健品中的应用。本发明的具有改善睡眠功能的组合物可用于食品或保健食品的制备,剂型可以是研磨粉、饮料、固体饮料、口服液、胶囊剂、片剂、粉剂、颗粒剂等,添加量为所需量。
因此,本发明具有如下有益效果:本发明的具有改善睡眠功能的组合物以药食同源的天然中药研制而成,通过各组分的协同增效,无毒副作用,具有较好的改善睡眠的效果。疗效 确切。
具体实施方式
下面结合实施例,进一步说明本发明的技术方案。
以下实施例中所使用的原料购自广州市清平药材市场。
实施例1
一种具有改善睡眠功能的组合物,其由以下组分混合而成:4份酸枣仁,12份桂圆,4份茯苓,9份百合,2份开边红莲,28份黑芝麻,16份山药,22份燕麦,2份抗性糊精,1份低聚果糖。
实施例2
一种具有改善睡眠功能的组合物,其由以下组分混合而成:5份酸枣仁,11份桂圆,5份茯苓,8份百合,3份开边红莲,27份黑芝麻,17份山药,21份燕麦,3份抗性糊精,2份低聚果糖。
实施例3
一种具有改善睡眠功能的组合物,其由以下组分混合而成:6份酸枣仁,10份桂圆,6份茯苓,7份百合,4份开边红莲,26份黑芝麻,18份山药,20份燕麦,4份抗性糊精,1份低聚果糖。
实施例4
一种具有改善睡眠功能的组合物,其由以下组分混合而成:7份酸枣仁,9份桂圆,7份茯苓,6份百合,5份开边红莲,25份黑芝麻,19份山药,19份燕麦,4份抗性糊精,2份低聚果糖。
实施例5
一种具有改善睡眠功能的组合物,其由以下组分混合而成:8份酸枣仁,8份桂圆,8份茯苓,5份百合,6份开边红莲,24份黑芝麻,20份山药,18份燕麦,3份抗性糊精,1份低聚果糖。
实施例6
一种具有改善睡眠功能的组合物,其由以下组分混合而成:4份酸枣仁,10份桂圆,4份茯苓,6份百合,3份开边红莲,20份黑芝麻,22份山药,20份燕麦,2份抗性糊精,2份低聚果糖。
实施例7
一种具有改善睡眠功能的组合物,其由以下组分混合而成:6份酸枣仁,10份桂圆,6份 茯苓,7份百合,4份开边红莲,24份黑芝麻,19份山药,20份燕麦,3份抗性糊精,1份低聚果糖。
本发明的具有改善睡眠功能的组合物具体应用方法为:在普通食品和保健食品的制备过程中直接按所需量添加即可,普通食品和保健食品的剂型可以是研磨粉、饮料、固体饮料、口服液、胶囊剂、片剂、粉剂、颗粒剂等,其剂型不受限制。
下面通过动物药理试验以证明本发明的实际效果:
1材料与方法
1.1动物
清洁级ICR雄性小白鼠,体重18.0~22.0g,由广东省医学实验动物中心提供,合格证号SCXK(粤)2013-0002。动物饲料购自广东省医学实验动物中心,合格证号SCXK(粤)2013-0002。小鼠饲养环境为温度25~28℃,相对湿度70%~85%,自然通风,光照/黑暗各12h,自由摄食,饮水。
1.2药品
按实施例7重量份的比例混合药材,加10倍量的水煎煮提取两次,合并水提液,浓缩,干燥,粉碎,得提取物干浸膏粉(记为YMF)。
1.3方法
1.3.1YMF对小鼠直接睡眠的影响
体重为18.0~22.0g的40只小鼠随机分为对照组及YMF低、中、高剂量组,每组10只。对照组每日灌胃给予0.5%羧甲基纤维素钠20mL/kg,YMF低、中、高剂量组分别灌胃给予YMF0.2、0.4、0.8g/kg,每日1次,连续灌胃30天。末次药后15min观察各组小鼠是否出现睡眠现象,记录入睡动物数及睡眠时间。
1.3.2YMF对阈剂量戊巴比妥钠睡眠时间的影响
体重为18.0~22.0g的40只小鼠随机分为对照组及YMF低、中、高剂量组,每组10只。对照组每日灌胃给予0.5%羧甲基纤维素钠20mL/kg,YMF低、中、高剂量组分别灌胃给予YMF0.2、0.4、0.8g/kg,每日1次,连续灌胃30天。末次药后15min,各组动物腹腔注射戊巴比妥钠45mg/kg,以翻正反射消失为指标,观察小鼠的睡眠时间。
1.3.3YMF对阈下剂量戊巴比妥钠睡眠发生率的影响
体重为18.0~22.0g的40只小鼠随机分为对照组及YMF低、中、高剂量组,每组10只。对照组每日灌胃给予0.5%羧甲基纤维素钠20mL/kg,YMF低、中、高剂量组分别灌胃给予YMF0.2、0.4、0.8g/kg,每日1次,连续灌胃30天。末次药后15min,各组动物腹腔注射戊巴 比妥钠25mg/kg,记录30min内入睡动物数,计算入睡动物发生率。
1.3.4YMF对巴比妥钠睡眠潜伏期的影响
体重为18.0~22.0g的40只小鼠随机分为对照组及YMF低、中、高剂量组,每组10只。对照组每日灌胃给予0.5%羧甲基纤维素钠20mL/kg,YMF低、中、高剂量组分别灌胃给予YMF0.2、0.4、0.8g/kg,每日1次,连续灌胃30天。末次药后15min,各组动物腹腔注射巴比妥钠250mg/kg,以翻正反射消失为指标,观察小鼠睡眠潜伏期。
1.3.5统计方法
数据的统计处理采用SPSS10.0统计软件中单因素方差分析进行均值比较,除了入睡动物发生率应用卡方检验外,其它指标均采用组间比较t检验。
2结果
2.1YMF对小鼠直接睡眠的影响
对照组动物行为活动自如,未见异常姿势、步态,无流涎、肌颤等现象发生。与对照组比较,YMF给小鼠连续灌胃30天,除了个别动物出现活动减少,均未出现明显嗜睡症状,入睡动物数及睡眠时间均无显著差异(P>0.05),结果见表1。
表1 YMF对小鼠直接睡眠的影响
2.2YMF对阈剂量戊巴比妥钠睡眠时间的影响
与对照组比较,YMF0.4、0.8g/kg组小鼠睡眠时间明显延长(P<0.05或P<0.01),0.2g/kg组小鼠睡眠时间无显著性差异(P>0.05),结果见表2。
表2 YMF对阈剂量g/kg睡眠时间的影响
注:与对照组比较*P<0.05,**P<0.01
2.3YMF对阈下剂量戊巴比妥钠睡眠发生率的影响
与对照组比较,YMF0.4、0.8g/kg组睡眠发生率明显提高(P<0.05或P<0.01),0.2g/kg组小鼠的睡眠发生率均无显著差异(P>0.05),结果见表3。
表3 YMF对阈下剂量戊巴比妥钠睡眠发生率的影响
注:与对照组比较*P<0.05,**P<0.01
2.4YMF对巴比妥钠睡眠潜伏期的影响
与对照组比较,YMF0.4、0.8g/kg组小鼠睡眠潜伏期明显缩短(P<0.05或P<0.01),0.2g/kg组小鼠睡眠潜伏期无显著性差异(P>0.05),结果见表4。
表4 YMF对巴比妥钠睡眠潜伏期的影响
注:与对照组比较*P<0.05,**P<0.01。
Claims (4)
1.一种药食同源的具有改善睡眠功能的组合物,其特征在于,所述具有改善睡眠功能的组合物由以下重量份的组分组成:4-8份酸枣仁,8-12份桂圆,4-8份茯苓,5-9份百合,2-6份开边红莲,20-28份黑芝麻,16-22份山药,18-22份燕麦,2-4份抗性糊精,1-2份低聚果糖。
2.根据权利要求1所述的一种具有改善睡眠功能的组合物,其特征在于,所述具有改善睡眠功能的组合物由以下重量份的组分组成:5-7份酸枣仁,9-11份桂圆,5-7份茯苓,6-8份百合,3-5份开边红莲,22-26份黑芝麻,18-21份山药,19-21份燕麦,2-4份抗性糊精,1-2份低聚果糖。
3.根据权利要求1所述的一种具有改善睡眠功能的组合物,其特征在于,所述具有改善睡眠功能的组合物由以下重量份的组分组成:6份酸枣仁,10份桂圆,6份茯苓,7份百合,4份开边红莲,24份黑芝麻,19份山药,20份燕麦,3份抗性糊精,1份低聚果糖。
4.根据权利要求1-3所述的具有改善睡眠功能的组合物在食品及保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610342991.0A CN105995425A (zh) | 2016-05-16 | 2016-05-16 | 一种药食同源的具有改善睡眠功能的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610342991.0A CN105995425A (zh) | 2016-05-16 | 2016-05-16 | 一种药食同源的具有改善睡眠功能的组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105995425A true CN105995425A (zh) | 2016-10-12 |
Family
ID=57096088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610342991.0A Pending CN105995425A (zh) | 2016-05-16 | 2016-05-16 | 一种药食同源的具有改善睡眠功能的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105995425A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110663959A (zh) * | 2019-11-01 | 2020-01-10 | 辽宁太爱肽生物工程技术有限公司 | 一种供失眠人群食用的含肽组合物及应用 |
CN111194913A (zh) * | 2020-01-15 | 2020-05-26 | 上海拜姿实业有限公司 | 一种改善睡眠的组合物、其制备方法及其应用 |
CN111616357A (zh) * | 2020-06-03 | 2020-09-04 | 华熙生物科技股份有限公司 | 基于药食同源的gaba补脾安神组合物、制剂及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101107995A (zh) * | 2007-08-09 | 2008-01-23 | 于洪文 | 一种中药保健袋泡饮品 |
CN102940768A (zh) * | 2012-09-03 | 2013-02-27 | 吉林一正药业集团有限公司 | 一种改善睡眠的组合物及其制备方法和应用 |
CN103110709A (zh) * | 2011-11-16 | 2013-05-22 | 北京康比特体育科技股份有限公司 | 一种改善睡眠的组合物及其制备方法 |
CN103689563A (zh) * | 2012-09-28 | 2014-04-02 | 天津红日药业股份有限公司 | 一种有助于改善睡眠的养生保健食品配方及其制备方法 |
CN104256632A (zh) * | 2014-07-11 | 2015-01-07 | 赛珂睿德生物医药科技(上海)有限公司 | 一种改善睡眠的保健品 |
CN105168519A (zh) * | 2015-09-23 | 2015-12-23 | 北华大学 | 具有改善睡眠功能的组合物及其制备方法和应用 |
-
2016
- 2016-05-16 CN CN201610342991.0A patent/CN105995425A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101107995A (zh) * | 2007-08-09 | 2008-01-23 | 于洪文 | 一种中药保健袋泡饮品 |
CN103110709A (zh) * | 2011-11-16 | 2013-05-22 | 北京康比特体育科技股份有限公司 | 一种改善睡眠的组合物及其制备方法 |
CN102940768A (zh) * | 2012-09-03 | 2013-02-27 | 吉林一正药业集团有限公司 | 一种改善睡眠的组合物及其制备方法和应用 |
CN103689563A (zh) * | 2012-09-28 | 2014-04-02 | 天津红日药业股份有限公司 | 一种有助于改善睡眠的养生保健食品配方及其制备方法 |
CN104256632A (zh) * | 2014-07-11 | 2015-01-07 | 赛珂睿德生物医药科技(上海)有限公司 | 一种改善睡眠的保健品 |
CN105168519A (zh) * | 2015-09-23 | 2015-12-23 | 北华大学 | 具有改善睡眠功能的组合物及其制备方法和应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110663959A (zh) * | 2019-11-01 | 2020-01-10 | 辽宁太爱肽生物工程技术有限公司 | 一种供失眠人群食用的含肽组合物及应用 |
CN111194913A (zh) * | 2020-01-15 | 2020-05-26 | 上海拜姿实业有限公司 | 一种改善睡眠的组合物、其制备方法及其应用 |
CN111616357A (zh) * | 2020-06-03 | 2020-09-04 | 华熙生物科技股份有限公司 | 基于药食同源的gaba补脾安神组合物、制剂及其应用 |
CN111616357B (zh) * | 2020-06-03 | 2022-08-26 | 华熙生物科技股份有限公司 | 基于药食同源的gaba补脾安神组合物、制剂及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103784611B (zh) | 一种具有改善睡眠帮助缓解压力的组合物及其应用 | |
CN103054044B (zh) | 一种改善睡眠的保健食品组合物 | |
CN104998098B (zh) | 一种改善睡眠的固体饮料及制备方法 | |
CN102335330B (zh) | 一种治疗失眠的中药组合物 | |
CN101284122A (zh) | 一种抗水土不服的软胶囊 | |
CN102106998B (zh) | 一种治疗失眠的中药 | |
CN101711810A (zh) | 一种用于改善睡眠、提高免疫的制剂 | |
CN104873745A (zh) | 一种治疗失眠的中药及制备方法 | |
CN105995425A (zh) | 一种药食同源的具有改善睡眠功能的组合物及其应用 | |
CN103566045A (zh) | 改善睡眠的药物组合物及其制备方法 | |
CN101181054A (zh) | 一种改善睡眠的保健食品 | |
CN105167098A (zh) | 一种改善睡眠的保健食品及其制备方法 | |
CN105963547A (zh) | 一种治疗失眠的保健药酒及其制备方法 | |
CN103446272B (zh) | 一种改善睡眠的组合物及其制备方法和用途 | |
CN104824293A (zh) | 一种采用食用植物作为成分制成的抗失眠代用茶的制备方法 | |
CN105267723A (zh) | 一种具有改善睡眠功效的玛咖组方及其制备方法 | |
CN103800888A (zh) | 一种治疗神经衰弱症的中药组合物 | |
CN101057948B (zh) | 一种具有健脑益智、养心安神的中药制剂及其制备方法 | |
CN104706881A (zh) | 一种具有调节睡眠功能的保健品 | |
CN104824292A (zh) | 一种采用食用植物作为成分制成的抗失眠代用茶 | |
CN107496808A (zh) | 用于治疗神经衰弱的中药组合物及其制备方法 | |
CN108041397A (zh) | 一种提升睡眠质量的固体饮料 | |
CN100360152C (zh) | 一种治疗失眠症的药物组合物及其制备方法 | |
CN106616955A (zh) | 一种改善睡眠的保健品的制作方法 | |
CN101313975B (zh) | 抗神经衰弱的药酒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DD01 | Delivery of document by public notice |
Addressee: GUANGZHOU HAOXIAOXIN MEDICAL EQUIPMENT CO., LTD. Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
C06 | Publication | ||
PB01 | Publication | ||
DD01 | Delivery of document by public notice |
Addressee: GUANGZHOU HAOXIAOXIN MEDICAL EQUIPMENT CO., LTD. Document name: Notification of Publication of the Application for Invention |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |
|
RJ01 | Rejection of invention patent application after publication |